financetom
Business
financetom
/
Business
/
Bluebird bio, Carlyle-SK Deal Clears Regulatory Hurdles
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bluebird bio, Carlyle-SK Deal Clears Regulatory Hurdles
May 26, 2025 1:46 AM

05:07 AM EDT, 05/06/2025 (MT Newswires) -- Bluebird bio (BLUE), Carlyle (CG), SK Capital Partners and Beacon Parent said late Monday that all required regulatory approvals have been received for the Bluebird bio's acquisition by Carlyle and SK Capital.

The companies said no additional approvals are needed, and the merger is expected to close soon on May 12.

Under the deal, Bluebird bio's shareholders will receive $3 per share in cash upfront and a contingent value right worth up to $6.84 per share, based on future sales milestones, bringing the total potential value to $9.84 per share.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved